St. Jude/Ventritex revised merger deal valued at $365 mil., 28% lower than October 1996 pact.
This article was originally published in The Gray Sheet
ST. JUDE/VENTRITEX $365 MIL. REVISED MERGER DEAL values Ventritex 28% lower than an original October 1996 agreement which was worth $505 mil. St. Jude Medical announced March 31 that it amended the deal to reflect the negative impact on the Ventritex business of component failures in two models of its Cadence implantable cardioverter defibrillators. The merger is expected to close in the second quarter, pending Ventritex shareholder approval.
You may also be interested in...
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
If the tools are not in place by the end of 2020 to allow diagnostics companies to comply with the EU IVDR, the 2022 compliance deadline should be delayed, say EU notified bodies.